Barrier Therapeutics
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Barrier Therapeutics
RXi Thinks Self-Delivering RNAi Could Be The Ticket In A Tricky Field
Biotech's asymmetrical, shorter RNAi therapeutics are water-soluble and therefore can be self-delivering. Lead candidate RXI-109 is being studied in both hypertrophic and retinal scarring, but the firm has new funding that could help it move into oncology.
JJDC Strategy Emphasizes the J & the J
Under the leadership of new president David Holveck, Johnson & Johnson Development Corp. is aligning its strategy more closely with the needs and wants of J&J's many companies.
Movetis Takes GI from J&J
VCs love a part-baked start-up, and one of the best places to find them is within Big Pharma. So it was that Belgium-based Movetis NV raised a record €49 million ($63.4 million) A round in January with a bunch of gastrointestinal-focused assets from Johnson & Johnson.
Endotis Pharma
Endotis Pharma joins the growing ranks of firms focused on glycoscience, or the science of sugars. Endotis' expertise is twofold: in understanding and regulating protein-sugar interactions, and in synthesizing small sugar-based drugs, or "glycodrugs," which can disrupt these interactions.